GSK’sGSK-3.16%decrease; red down pointing triangle blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the likelihood for the treatment to return to ...

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer ...

GSK (NYSE:GSK) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its antibody-drug conjugate Blenrep as a late-line option and as part ...

GSK had great expectations for Blenrep after its accelerated FDA approval in 2020 as a fourth-line or later treatment for multiple myeloma, which came crashing down with the failure of the DREAMM ...

In the study, a treatment combination including the drug, called Blenrep, cut the risk of death by 42% among patients with multiple myeloma, a result that was statistically significant and that ...

The Blenrep results presented Monday are from a Phase 3 test, DREAMM-7, that enrolled nearly 500 patients whose multiple myeloma relapsed or was refractory to at least one earlier line of therapy.

The DREAMM-7 trial showed Blenrep with BorDex lowered death risk in relapsed/refractory multiple myeloma vs. standard treatment. A phase 3 study in newly diagnosed transplant-ineligible multiple ...

Blenrep combo nearly tripled PFS to 36.6 months vs 13.4 months in DREAMM-7. Blenrep cut risk of death by 42% vs comparator in DREAMM-7 at 39.4-month median follow-up. Up Next: Get 5 Dark Horse ...

BLENREP is a first-in-class anti-BCMA (B-cell maturation antigen) therapy for patients whose disease has progressed despite prior treatment with an immunomodulatory agent, proteasome inhibitor and ...

The DREAMM-7 trial met its secondary endpoint, highlighting Blenrep's potential to extend patient survival. Blenrep, the first BCMA-targeting therapy, was FDA-approved in 2020 for relapsed/refractory ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple myeloma. News & Perspective Tools & Reference CME/CE More ...

GSK said a late-stage trial of its blood-cancer drug Blenrep showed positive results. G SK’s blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the ...